Reporter

December 5, 2019

Multisite study focuses on opioid use during pregnancy

The Vanderbilt Maternal Addiction Recovery Program is participating in a 12-site clinical trial that will compare two forms of the medication buprenorphine in treating opioid use disorder during pregnancy, and the results could have a potentially significant impact on clinical practice.

December 5, 2019

Balko lands Mary Kay Foundation grant for breast cancer research

Vanderbilt-Ingram Cancer Center’s Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.

John Wilson, PhD, center, assistant professor of Chemical and Biomolecular Engineering at Vanderbilt University, received a $50,000 research grant at the 2019 Vanderbilt-Ingram Cancer Center Ambassador Breakfast after delivering the winning pitch on his project “Engineering Smart Technologies for Cancer Immunotherapy.” Pictured with Wilson are VICC Ambassadors Hank Ingram and Sydney Ball.
December 5, 2019

Winning pitch

John Wilson, PhD, assistant professor of Chemical and Biomolecular Engineering at Vanderbilt University, received a $50,000 research grant at the 2019 Vanderbilt-Ingram Cancer Center Ambassador Breakfast.

Patrick Hu, MD, PhD, has been named assistant dean for Physician-Researcher Training and director of the Office for Medical Student Research.
December 4, 2019

Genetic screen in worms reveals critical step in insulin synthesis

The identification of a protein important for insulin synthesis may hold clues for understanding the pathogenesis of diabetes.

December 2, 2019

New VUMC service education focuses on strategies to “power up” positivity

The fourth module of Defining Personalized Care – Elevating Our Culture of Service, focuses on the effect positivity can bring to an individual’s own well-being and to those they serve, including colleagues.

November 27, 2019

Zantac recalled for carcinogen levels above FDA standards

The popular heartburn drug ranitidine, commonly known as Zantac, was voluntarily recalled due to the contamination of a human carcinogen that could potentially cause cancer. The recall includes oral tablets, capsules, and syrup.